If you have been reading about receptor targets and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
== Limitations and safety == Clinical trials comparing lumbar facet arthroplasty with the TOPS system to lumbar fusion have reported overall complication and reoperation rates that are broadly similar between procedures. Reported adverse events include infection, dural tear, pedicle screw loosening or implant-related complications, and the need for revision surgery. In randomized studies with two-year follow-up, symptomatic adjacent segment degeneration has been reported more frequently after fusion than after facet arthroplasty. Appropriate patient selection remains important, as the device is not indicated for individuals with high-grade spondylolisthesis, severe osteoporosis, or significant spinal deformity.
Adenosine-to-inosine (A-to-I) modifications contribute to nearly 90% of all editing events in RNA. The deamination of adenosine is catalyzed by the double-stranded RNA-specific adenosine deaminase (ADAR), which typically acts on pre-mRNAs. The deamination of adenosine to inosine disrupts and destabilizes the dsRNA base pairing, therefore rendering that particular dsRNA less able to produce siRNA, which interferes with the RNAi pathway. The wobble base pairing causes deaminated RNA to have a unique but different structure, which may be related to the inhibition of the initiation step of RNA translation. Studies have shown that I-RNA (RNA with many repeats of the I-U base pair) recruits methylases that are involved in the formation of heterochromatin and that this chemical modification heavily interferes with miRNA target sites. There is active research into the importance of A-to-I modifications and their purpose in the novel concept of epitranscriptomics, in which modifications are made to RNA that alter their function. A long established consequence of A-to-I in mRNA is the interpretation of I as a G, therefore leading to functional A-to-G substitution, e.g. in the interpretation of the genetic code by ribosomes. Newer studies, however, have weakened this correlation by showing that inosines can also be decoded by the ribosome (although in a lesser extent) as adenosines or uracils. Furthermore, it was shown that I's lead to the stalling of ribosomes on the I-rich mRNA.
Cyproheptadine is a potent antihistamine or inverse agonist of the histamine H1 receptor. It also has anticholinergic, antiserotonergic, antidopaminergic, and local anesthetic activities. In one study, cyproheptadine had about the same affinity for the serotonin 5-HT2A and 5-HT2B receptors as for the histamine H1 receptor, about 8-fold selectivity for the histamine H1 receptor over the serotonin 5-HT2C receptor, about 2- to 8-fold selectivity for the H1 receptor over the muscarinic acetylcholine receptors, and about 4- to 52-fold selectivity for the histamine H1 receptor over the dopamine receptors. The drug shows lower affinity for α-adrenergic receptors and little to no affinity for the monoamine transporters. Of the serotonin receptors, it is an especially potent antagonist of the 5-HT2 receptors. This is thought to underlie its effectiveness in the treatment of serotonin syndrome. However, it is possible that blockade of 5-HT1 receptors may also contribute to its effectiveness in serotonin syndrome. Cyproheptadine has been reported to block 85% of 5-HT2 receptors in the human brain at a dose of 4 mg three times per day (12 mg/day total) and to block 95% of 5-HT2 receptors in the human brain at a dose of 6 mg three times per day (18 mg/day total) as measured with positron emission tomography (PET). The most widely used dose of cyproheptadine for serotonin syndrome has been said to be 4 mg, though doses of up to 16 mg have been used.
Cadmium at The Periodic Table of Videos (University of Nottingham) ATSDR Case Studies in Environmental Medicine: Cadmium Toxicity Archived 18 December 2020 at the Wayback Machine U.S. Department of Health and Human Services National Institute for Occupational Safety and Health – Cadmium Page NLM Hazardous Substances Databank – Cadmium, Elemental
== Clinical significance == Urothelium is susceptible to carcinoma. Because the bladder is in contact with urine for extended periods, chemicals that become concentrated in the urine can cause bladder cancer. For example, cigarette smoking leads to the concentration of carcinogens in the urine and is a leading cause of bladder cancer. Aristolochic acid, a compound found in plants of the family Aristolochiaceae, also causes DNA mutations and is a cause of liver, urothelial and bladder cancers. Occupational exposure to certain chemicals is also a risk factor for bladder cancer. This can include aromatic amines (aniline dye), polycyclic aromatic hydrocarbons, and diesel engine exhaust.
Sources: en.wikipedia.org
== History == The study of lichen acids related to protolichesterinic acid began in 1845, when Schnedermann and Wilhelm Knop isolated lichesterinic acid from Cetraria islandica var. vulgaris. They determined it had a melting point around 120 °C (248 °F) and established its composition as C19H32O4. Further research by H. Sinnhold in 1898 worked with pure lichesterinic acid (melting point 124.5–125 °C). In 1900, Oswald Hesse isolated three varieties (α-, β-, and γ-) of lichesterinic acid from Cetraria islandica, with specific rotations of +27.9°, +27.9°, and +16° respectively. Protolichesterinic acid was first isolated at the beginning of the 20th century by Friedrich Wilhelm Zopf from the lichen Cetraria cucullata (now known as Cladocetraria cucullata). Zopf initially found it alongside usnic acid and noticed that while it showed similarities to lichesterinic acid in some properties, it differed significantly in melting point and other characteristics. The compound was named "protolichesterinic acid" to reflect its close relationship to lichesterinic acid, and the discovery was published in Liebigs Annalen in 1902. After obtaining it in crystalline form through extraction with ether and recrystallization from warm benzol, Zopf determined that protolichesterinic acid formed thin, rhombic, pearly plates that melted at 103–104 °C (217–219 °F), lower than lichesterinic acid's melting point of 124–125 °C (255–257 °F).
H3A (aq) + H2O (l) ⇌ H3O+ (aq) + H2A− (aq) Ka1 H2A− (aq) + H2O (l) ⇌ H3O+ (aq) + HA2− (aq) Ka2 HA2− (aq) + H2O (l) ⇌ H3O+ (aq) + A3− (aq) Ka3 An inorganic example of a triprotic acid is orthophosphoric acid (H3PO4), usually just called phosphoric acid. All three protons can be successively lost to yield H2PO−4, then HPO2−4, and finally PO3−4, the orthophosphate ion, usually just called phosphate. Even though the positions of the three protons on the original phosphoric acid molecule are equivalent, the successive Ka values differ since it is energetically less favorable to lose a proton if the conjugate base is more negatively charged. An organic example of a triprotic acid is citric acid, which can successively lose three protons to finally form the citrate ion. Although the subsequent loss of each hydrogen ion is less favorable, all of the conjugate bases are present in solution. The fractional concentration, α (alpha), for each species can be calculated. For example, a generic diprotic acid will generate 3 species in solution: H2A, HA−, and A2−. The fractional concentrations can be calculated as below when given either the pH (which can be converted to the [H+]) or the concentrations of the acid with all its conjugate bases:
=== Specific proposals === A variety of government task forces, expert panels, private institutions, politicians, and journalists have made recommendations for reducing the deficit and slowing the growth of debt. Several organizations have compared the future impact of these plans on the deficit, debt, and economy. One helpful way of measuring the impact of the plans is to compare them in terms of revenue and expense as a percentage of GDP over time, in total and by category. This helps illustrate how the different plan authors have prioritized particular elements of the budget.
=== Pharmacodynamics === Both THC and CBN activate the CB1 (Ki = 211.2 nM) and CB2 (Ki = 126.4 nM) receptors. Each compound acts as a low affinity partial agonist at CB1 receptors with THC demonstrating 5x–10× greater affinity to the CB1 receptor. Like THC, CBN has a higher selectivity for CB2 receptors which are located throughout the central and peripheral nervous system, but are primarily associated with immune function. CB2 receptors are known to be located on immune cells throughout the body, including macrophages, T cells, and B cells. These immune cells have been shown to decrease production of immune-related chemical signals (e.g., cytokines) or undergo apoptosis as a consequence of CB2 agonism by CBN. In cell culture, CBN demonstrates antimicrobial effects, particularly in instances of antibiotic-resistant bacteria. CBN has also been reported to act as an ANKTM1 channel agonist at high concentrations (>20nM). While some phytocannabinoids have been shown to interact with nociceptive and immune-related signaling via transient receptor potential channels (e.g., TRPV1 and TRPM8), there is currently limited evidence to suggest that CBN acts in this way. In preclinical rodent studies, CBN, anandamide and other CB1 agonists have demonstrated inhibitory effects on GI motility, reversible via CB1R blockade (i.e., antagonism). In considering the efficacy of cannabis-based products, there remains controversy surrounding a concept termed “the entourage effect”.
Sources: en.wikipedia.org
He strengthened the squad by signing Alexis Sánchez from Barcelona in July 2014, who started in the 2014 FA Community Shield that Arsenal won by beating Manchester City 3–0, and during the course of 2014–15, Wenger promoted Francis Coquelin and Héctor Bellerín into the first team. Wenger won his sixth FA Cup in May 2015, which placed him alongside George Ramsay as the most successful manager in the competition's history. Wenger guided the club to an improved third place in the league that season, and the club saw further improvement in the 2015–16 season as they finished as league runners-up, while retaining the FA Community Shield by defeating Chelsea 1–0.
President Donald Trump said that Vance, Witkoff, and former senior presidential adviser Jared Kushner are talking to intermediaries in Pakistan on ending the war. He also called the Iran proposal a "significant step" ahead of his Tuesday deadline for Iran to reopen the Strait of Hormuz. Earlier on 7 April, Trump warned that "a whole civilization will die tonight" and will "never be brought back" if Iran does not agree to a deal by midnight (GMT). Later during the day, amidst a two-week ceasefire plan by Pakistan, White House Press Secretary Karoline Leavitt stated that Trump was made aware of the plan. Additionally, it was reported by CBS News that Vance would serve as the US interlocutor in the ceasefire talks. On 8 April, Trump threatened to impose a 50% tariff on any country 'supplying military weapons to Iran.' Also on 8 April, Trump threatened that if no deal is reached by Wednesday when the ceasefire expires, the fighting may resume. On 21 April, Trump said that Iran has violated the ceasefire "numerous times." At an 8 April press conference, Trump said the US will work closely with Iran, talking about the tariff, sanctions and relief. In regard to the Iranian uranium, he stated: "There will be no enrichment of Uranium, and the United States will, working with Iran, dig up and remove all of the deeply buried (B-2 Bombers) Nuclear 'Dust.'" He later added that Lebanon is not included in the ceasefire agreement and that Hezbollah will need to be dealt with: Yeah, they [Lebanon] were not included in the deal . . Because of Hezbollah. They were not included in the deal.
=== Underdiagnosis === Despite increasing clinical documentation, symptomatic Tarlov cysts remain frequently underdiagnosed. This has been attributed to persistent misconceptions in clinical practice and the common perception that these cysts represent incidental findings. Radiologists often omit documenting them on MRI reports or describe them as clinically insignificant, which may contribute to delayed or missed diagnoses. Smaller cysts, in particular, are more likely to be overlooked.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Mass spectrometry provides a mass value that can be compared with the expected value, while peptide mapping examines fragmentation patterns. Together these techniques support identity claims better than a single measurement can.